Volume 24 - Issue 7 - July 2011
Podiatric technology continues to advance and the profession has seen recent innovations in areas such as wound care, surgery and the diabetic foot. Experts in various aspects of podiatry provide insights on acellular dermal matrices, a hammertoe implant, a diabetic insole and other podiatric advances.
Wound Care Q&A »
Wound debridement is the foundation for successful and swift wound healing. Appropriate and timely wound debridement facilitates infection control by removing the biofilm over wound surfaces. Our expert panelists discuss best practices in wound debridement by reviewing the clinical evidence for wound debridement, patient education and insights on the vascular workup of patients with wounds.
Surgical Pearls »
Arthrodesis of the first metatarsophalangeal joint (MPJ) was first advocated in 1894 by Clutton for severe, painful hallux valgus.1 McKeever refined the technique in 1952 using intramedullary screw fixation, which is currently the gold standard for treatment of advanced arthritis and/or significant deformities of the hallux.2 Common indications for arthrodesis include stage 3 hallux rigidus (osteoarthritis), rheumatoid arthritis, failed first MPJ implants, severe hallux valgus deformities and post-traumatic arthritis.3,4
News and Trends »
New evidence-based guidelines for painful diabetic neuropathy, recently published in Neurology, examine the efficacy of various types of modalities to relieve the pain of diabetic neuropathy. The authors note that pregabalin (Lyrica, Pfizer) is effective for Level A neuropathy while venlafaxine (Effexor, Pfizer), duloxetine (Cymbalta, Eli Lilly), amitriptyline (Elavil, Merck), gabapentin (Neurontin, Pfizer), valproate (Depacon, Abbott Laboratories), opioids and capsaicin are effective for Level B neuropathy.
- « Previous
- | Page 3 of 3 |
- Next »